PTGS-2–PTGER2/4 Signaling Pathway Partially Protects From Diabetogenic Toxicity of Streptozotocin in Mice

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 6.
FIG. 6.

Protective effects of PTGER2/PTGER4 agonists. A: Effect of PTGER2 and PTGER4 agonists on STZ-induced hyperglycemia in PTGS-2−/− and wild-type mice (CTRL). Mice were treated for 3 days, starting 24 h before STZ application (200 mg/kg BW), with a combination of PTGER2-selective agonist ONO-AE1-259-01 (40 ng/kg) and PTGER4-selective agonist ONO-AE1-329 (40 ng/kg) (PTGER-Ag). On day 4, blood glucose concentrations were measured by glucose meter. Data are shown as mean ± SEM; n = 6. *P < 0.05 vs. untreated controls; #P < 0.05 vs. STZ-treated PTGS-2−/−; $P < 0.05 vs. STZ-treated CTRL. B: Effect of PTGER2 and PTGER4 agonists on survival of STZ-treated PTGS-2−/− mice. PTGS-2−/− mice were treated 1 day before STZ application (200 mg/kg BW) and then daily with a combination of PTGER2-selective agonist ONO-AE1-259-01 (40 ng/kg) and PTGER4-selective agonist ONO-AE1-329 (40 ng/kg) (PTGER-Ag) or vehicle. Mice were kept under standard conditions for 10 days. Data are shown as mean ± SEM; n = 10.

This Article

  1. Diabetes vol. 61 no. 7 1879-1887